Navigation Links
Genesis Pharmaceuticals Changes Auditors
Date:3/11/2008

LAIYANG, China, March 11 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GTEC) ("Genesis" or the "Company"), a pharmaceutical company with its principal operations in the People's Republic of China, announced that it changed auditors from Sherb & Co., LLP to Moore Stephens Wurth Frazer & Torbet, LLP.

The client-auditor relationship between Genesis Pharmaceuticals Enterprises, Inc. and Sherb & Co., LLP ended as of February 25, 2008 in regard to all accounting and auditing services, and all quarterly reporting up through and including February 25, 2008. All accounting and auditing services and all quarterly reports from February 25, 2008 on will be handled by Moore Stephens Wurth Frazer & Torbet, LLP. Sherb & Co., LLP, were Genesis' auditors for the fiscal years ended September 30, 2007 and September 30, 2006. There were no disagreements between Genesis Pharmaceuticals Enterprises, Inc. and Sherb & Co., LLP.

"We look forward to working with Moore Stephens and continuing to provide the investment community with timely and accurate financial information that reflects Genesis' activities," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises, Inc.

About Genesis Pharmaceuticals Enterprises

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged through its controlled affiliates in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing both western and Chinese herbal- based medical drugs in tablet, capsule and granule form. The Company maintains a representative office in the U.S. For more information, refer to http://www.Genesis-China.net .

Safe Harbor Statement

Certain statements set forth in this press release constitute "forward- looking statements." Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

For more information, please contact:

Genesis Pharmaceuticals Enterprises, Inc.

Ms. Elsa Sung CFO

Tel: +1-877-895-3650 x701

Email: genesispharm@gmail.com

CCG Elite Investor Relations, Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiogenesis Corporation Announces Rescheduled Fourth Quarter and Full Year 2007 Earnings Release
2. Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
3. Cardiogenesis Corporation to Report 2007 Fourth Quarter and Year-End Results on March 4th
4. Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine
5. Childrens Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis
6. Genesis Pharmaceuticals Announces Results for The First Quarter of Fiscal Year 2008
7. Cardiogenesis Receives FDA Approval for PEARL 5.0 Robotic Hand Piece
8. ThermoGenesis Corp. Reports First Quarter 2008 Results
9. Tissue Genesis Signs Exclusive Distribution and License Agreement with SpineSmith
10. Researchers chart the genetic mechanisms behind the genesis of fat cells
11. Genesis Technology Group Retains CCG Elite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 12, 2017   Divoti USA will engrave ... the standard of the latest FDA requirements, which stipulates new criteria ... Anyone in need of Medical ID jewelry such as Medical ID ... are engraved in terms of the new FDA requirements . ... Divoti offers this dark mark ...
(Date:10/11/2017)... CHICAGO , Oct. 11, 2017  Hill-Rom Holdings, ... its Aspen Surgical facility in Las Piedras, ... surgical scalpels and blades. ... confirmed that the facility sustained minor structural damage, temporary ... Hurricane Maria. Repairs have been completed, manufacturing operations have ...
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology: